CimenTEfeTHAkyelA, et al.Human endothelial cell-specific molecule-1 (Endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67:846–53.
2.
AkbogaMKCanpolatUYaylaC, et al.Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. Angiology. 2016;67:89–95.
3.
MallikaVGoswamiBRajappaM. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007;58:513–22.
4.
LibbyP. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
5.
DeveciOSKabakciGTulumenE, et al.The relationship between microalbuminuria and the presence and extent of coronary atherosclerosis. Angiology. 2010;61:184–91.
6.
YaylaCCanpolatUAkyelA, et al.Association Between platelet to lymphocyte ratio and saphenous vein graft disease. Angiology. 2016;67:133–8.
7.
AkbogaMKCanpolatUSahinarslanA, et al.Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015;240:110–4.
8.
KayaEBYorgunHCanpolatU, et al.Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis. 2010;213:178–83.
9.
CanpolatUAytemirKYorgunH, et al.The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace. 2015;17:1807–15.
10.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339–43.
11.
BaltaSMikhailidisDPDemirkolSCelikTOzturkCIyisoyA. Endocan and atherosclerosis. Angiology. 2015;66:490.
12.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.
